Wall Street analyst estimates for Cue Biopharma, Inc. (CUE): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the human immune system to address a spectrum of severe conditions, such as various cancers, chronic infectious diseases, and autoimmune disorders. The company's leading investigational therapeutic is CUE-101, a specialized fusion protein biologic.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 9 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 9 |
| Avg rating (1-5) | 1.00 |
Valuation Ratios
| Price / Book | 1.34 |
| EV / EBITDA | -0.27 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | $1.1M | $3.5M | $3.2M | $14.9M | $1.2M | $5.5M | $9.3M | $27.5M |
| Cost of Revenue | $202085 | $419568 | $28.5M | $27.5M | $33.5M | -$1.8M | 0 | $38.1M | 0 | 0 |
| Gross Profit | -$202085 | -$419568 | -$27.4M | -$24.0M | -$30.4M | $16.7M | $1.2M | -$32.6M | $9.3M | $27.5M |
| Research & Development | $5.7M | $18.9M | $28.5M | $27.5M | $33.5M | $41.3M | $38.6M | $40.8M | $36.3M | $37.7M |
| Selling, General & Admin | $2.0M | $4.3M | $11.3M | $12.7M | $14.7M | $17.3M | $16.2M | $16.7M | $14.6M | $16.2M |
| Operating Expenses | $7.7M | $23.2M | $39.8M | $12.7M | $14.7M | $60.4M | $54.5M | $19.5M | $50.8M | $54.0M |
| Operating Income | -$7.7M | -$23.2M | -$38.7M | -$36.8M | -$45.0M | -$43.7M | -$53.2M | -$52.1M | -$41.5M | -$26.5M |
| EBITDA | -$7.5M | -$22.8M | -$37.9M | -$36.0M | -$44.0M | -$45.4M | -$50.5M | -$46.1M | -$37.5M | -$22.3M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | $713815 | $1.2M | $796000 | $357000 |
| Pre-tax Income | -$7.7M | -$23.2M | -$38.2M | -$36.3M | -$44.6M | -$43.7M | -$53.0M | -$50.7M | -$40.7M | -$26.1M |
| Income Tax | 0 | 0 | $825000 | $412500 | $206250 | $495000 | 0 | 0 | 0 | $500000 |
| Net Income | -$7.7M | -$23.2M | -$39.0M | -$36.7M | -$44.8M | -$44.2M | -$53.0M | -$50.7M | -$40.7M | -$26.6M |
| EPS | $-11.10 | $-33.90 | $-58.20 | $-49.80 | $-46.80 | $-42.30 | $-44.70 | $-33.30 | $-21.60 | $-8.40 |
| EPS (Diluted) | $-11.10 | $-33.90 | $-58.20 | $-49.80 | $-46.80 | $-42.30 | $-44.70 | $-33.30 | $-21.60 | $-8.40 |
| Shares Outstanding (Diluted) | $688020 | $688020 | $671135 | $734726 | $956287 | $1.0M | $1.2M | $1.5M | $1.9M | $3.2M |
Price
| Price | $34.17 |
| Market Cap | $90M |
| Exchange | NASDAQ |
| Country | US |
Related companies: BRNS · COEP · EQ · IOBT · IPSC · MDCX · NRXP
Explore sector: Healthcare · Biotechnology
More sections of CUE: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks